Drug Profile
BRC 672
Latest Information Update: 09 Feb 2001
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antihypertensives
- Mechanism of Action Neuropeptide Y receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 09 Feb 2001 Profile reviewed but no significant changes made
- 10 Jul 1998 No-Development-Reported for Hypertension in Australia (Unknown route)
- 19 Sep 1995 New profile